Recovery Report: Frontier Communications Corp.'s Recovery Rating Profile Jan 13

  • ID: 2386677
  • January 2013
  • Standard & Poors
1 of 3

Standard & Poor's Ratings Services has updated its recovery analysis on Stamford, Conn.-based communications services provider Frontier Communications Corp. as part of ongoing surveillance, incorporating the recent lowering of the corporate credit rating to 'BB-'. While the recovery ratings remain unchanged following our review, we have revised the issue-level ratings to reflect the lower corporate credit rating. Our recovery analysis incorporates a simulated default scenario that contemplates a payment default occurring in 2017 caused by much greater-than-anticipated access-line losses, reducing the company's cash flow and liquidity and resulting in a payment default. The indentures for Frontier's various note issuances contain covenants which, among other things, limit its ability to incur indebtedness at its subsidiaries, create liens securing indebtedness, and merge...

Companies mentioned in this report are:
- Frontier Communications Corp.

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

- Frontier Communications Corp.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.